Physician profile
Dalys Gomez
NPI 1558367508
$5,574.59
in general payments reported to CMS, 2019-2025
29 companies · $982 in 2025
The $982 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $567 · 2021: $1,007 · 2022: $981 · 2023: $725 · 2024: $588 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,421.31 | 2020-2025 | Cuvitru, Takhzyro |
| Glaxosmithkline, LLC. | $1,119.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Csl Behring | $756.26 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Grifols USA, LLC | $344.77 | 2019-2025 | Xembify |
| Astrazeneca Pharmaceuticals LP | $221.41 | 2019-2024 | Airsupra, Fasenra |
| Shire North American Group INC | $205.45 | 2019 | |
| Optinose US, INC. | $176.65 | 2019-2025 | |
| Octapharma USA, INC. | $170.00 | 2022-2025 | Cutaquig, Panzyga, Octagam Immune Globulin (Human) |
| Novartis Pharmaceuticals Corporation | $152.60 | 2024-2025 | |
| Alk-Abello, INC | $150.02 | 2019-2023 | Odactra, Grastek, Ragwitek |
| Biocryst US Sales Co., LLC | $120.36 | 2021-2025 | Orladeyo |
| Kaleo, INC. | $110.04 | 2019-2024 | Auvi-Q |
| Pharming Healthcare, INC. | $93.42 | 2024-2025 | Ruconest |
| Gc Biopharma USA, INC. | $87.89 | 2025 | Alyglo |
| Regeneron Healthcare Solutions, INC. | $86.04 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.67 | 2021-2024 | |
| Ars Pharmaceuticals Operations, INC. | $43.67 | 2025 | Neffy |
| Amgen INC. | $41.00 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $36.55 | 2021-2022 | |
| Genentech USA, INC. | $33.63 | 2024 | Xolair |
| Paratek Pharmaceuticals, INC. | $24.80 | 2025 | Xhance |
| Uswm, LLC | $20.00 | 2021 | |
| Ionis Pharmaceuticals, INC. | $19.46 | 2025 | Dawnzera |
| Biocryst Pharmaceuticals, INC. | $18.85 | 2020 | |
| Adma Biomanufacturing LLC | $17.19 | 2020 | |
| Kedrion Biopharma, INC. | $16.99 | 2024 | Kedrab, Koate, Gammaked |
| Greer Laboratories, INC. | $14.97 | 2019 | |
| Mylan Specialty L.P. | $14.28 | 2021 | |
| Merck Sharp & Dohme LLC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalys Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.